Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MaiLi Define is a premium hyaluronic acid (HA)-based injectable dermal filler developed by Sinclair Pharma. It is part of the MaiLi portfolio, which includes Precise, Define, Volume, and Extreme. MaiLi Define contains 18 mg/ml of crosslinked hyaluronic acid and 0.3% lidocaine. It is manufactured using the patented OxiFree technology, which preserves long HA molecular chains through anaerobic crosslinking with BDDE (1,4-Butanediol diglycidyl ether), resulting in a supple, spring-like gel with high projection power and longevity. The product is indicated for filling deep wrinkles, such as perioral and marionette lines, and for enhancing lip volume and definition while maintaining natural dynamic facial expressions. It is a CE-marked medical device administered via deep intradermal injection or into the labial mucosa.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MaiLi Define.